- Home
- NPT vs CGEN Comparison
NPT vs CGEN Comparison
Compare NPT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | CGEN |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 148.7M |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NPT | CGEN |
|---|---|---|
| Price | $5.90 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.9M | 295.0K |
| Earning Date | 02-27-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $797,148,640.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.51 | N/A |
| 52 Week Low | $3.14 | $1.13 |
| 52 Week High | $13.48 | $2.38 |
Technical Indicators
Market Signals| Indicator | NPT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 42.27 |
| Support Level | $5.90 | $1.63 |
| Resistance Level | $7.00 | $1.82 |
| Average True Range (ATR) | 1.56 | 0.09 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 10.64 | 18.18 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.